CompletedPhase 2NCT00085475
Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma
Studying Dermatofibrosarcoma protuberans
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Allan T. van Oosterom, MD, PhD, MD, PhDUniversity Hospital, Gasthuisberg
- Intervention
- imatinib mesylate(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004
Study locations (7)
- Institut Jules Bordet, Brussels, Belgium
- U.Z. Gasthuisberg, Leuven, Belgium
- Institut Bergonie, Bordeaux, France
- CHU de la Timone, Marseille, France
- Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- Leiden University Medical Center, Leiden, Netherlands
- Christie Hospital NHS Trust, Manchester, England, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00085475 on ClinicalTrials.gov